{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T05:10:04Z","timestamp":1648962604658},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/cad.0b013e32835b9589","type":"journal-article","created":{"date-parts":[[2012,11,14]],"date-time":"2012-11-14T09:12:42Z","timestamp":1352884362000},"page":"198-203","source":"Crossref","is-referenced-by-count":4,"title":["Add-on-therapy with bevacizumab in children and adolescents with poor prognosis non-CNS solid tumors"],"prefix":"10.1097","volume":"24","author":[{"given":"Jasmin","family":"Pansy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Sovinz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herwig","family":"Lackner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Schwinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Urban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Benesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20210227","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14712590902817817","article-title":"Bevacizumab: current indications and future development for management of solid tumors.","volume":"9","author":"Jenab-Wolcott","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"R2-11-20210227","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1634\/theoncologist.2009-0250","article-title":"FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.","volume":"15","author":"Summers","year":"2010","journal-title":"Oncologist"},{"key":"R3-11-20210227","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA drug approval summary: bevacizumab (Avastin) as treatment for recurrent glioblastoma multiforme.","volume":"14","author":"Cohen","year":"2009","journal-title":"Oncologist"},{"key":"R4-11-20210227","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/pbc.22409","article-title":"Feasibility and tolerability of bevacizumab in children with primary CNS tumors.","volume":"54","author":"Reismuller","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R5-11-20210227","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/pbc.22868","article-title":"Bevacizumab and irinotecan in the treatment of children with recurrentrefractory medulloblastoma.","volume":"56","author":"Aguilera","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R6-11-20210227","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11060-010-0444-x","article-title":"Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.","volume":"103","author":"Parekh","year":"2011","journal-title":"J Neurooncol"},{"key":"R7-11-20210227","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/pbc.24006","article-title":"Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors.","volume":"59","author":"Peyrl","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R8-11-20210227","first-page":"985","article-title":"Bevacizumab in recurrent high-grade pediatric gliomas.","volume":"12","author":"Narayana","year":"2010","journal-title":"Neurooncology"},{"key":"R9-11-20210227","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2007.11.9230","article-title":"Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Childrens Oncology Group Study.","volume":"26","author":"Glade Bender","year":"2008","journal-title":"J Clin Oncol"},{"key":"R10-11-20210227","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdm510","article-title":"Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.","volume":"19","author":"Benesch","year":"2008","journal-title":"Ann Oncol"},{"key":"R11-11-20210227","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000137715","article-title":"Chemorefractory rhabdomyosarcoma treated with radiotherapy, bevacizumab, statins and surgery and maintenance with bevacizumab and chemotherapy.","volume":"31","author":"Linden","year":"2008","journal-title":"Onkologie"},{"key":"R12-11-20210227","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/pbc.23241","article-title":"Antiangiogenic treatment as a pre-operative management of alveolar soft-part sarcoma.","volume":"57","author":"Conde","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R13-11-20210227","doi-asserted-by":"crossref","first-page":"261589","DOI":"10.1155\/2008\/261589","article-title":"Outpatient and home chemotherapy with novel local control strategies in desmoplastic small round cell tumor.","volume":"2008","author":"Aguilera","year":"2008","journal-title":"Sarcoma"},{"key":"R15-11-20210227","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000321801","article-title":"Incidental resolution of a radiation-induced cavernous hemangioma of the brain following the use of bevacizumab in a child with recurrent medulloblastoma.","volume":"46","author":"Aguilera","year":"2010","journal-title":"Pediatr Neurosurg"},{"key":"R16-11-20210227","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.ijrobp.2008.12.032","article-title":"Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas.","volume":"75","author":"Liu","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R17-11-20210227","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood-2009-11-247056","article-title":"Rapid improvement of life-threatening capillary leak syndrome after stem cell transplantation by bevacizumab.","volume":"115","author":"Yabe","year":"2010","journal-title":"Blood"},{"key":"R18-11-20210227","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/pbc.21597","article-title":"Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome.","volume":"51","author":"Smith","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R19-11-20210227","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2146\/ajhp080455","article-title":"Understanding and managing the possible adverse effects associated with bevacizumab.","volume":"66","author":"Shord","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"R20-11-20210227","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/pbc.21866","article-title":"Reversible posterior leukencephalopathy syndrome in a child treated with bevacizumab.","volume":"52","author":"Levy","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R21-11-20210227","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1055\/s-0032-1301930","article-title":"Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature.","volume":"224","author":"Grunewald","year":"2012","journal-title":"Klin Padiatr"},{"key":"R22-11-20210227","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0029-1220738","article-title":"Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor.","volume":"221","author":"Calaminus","year":"2009","journal-title":"Klin Padiatr"},{"key":"R23-11-20210227","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdq331","article-title":"First report of effective and feasible treatment of multifocal lymphangiomatosis (Gorham-Stout) with bevacizumab in a child.","volume":"21","author":"Grunewald","year":"2010","journal-title":"Ann Oncol"},{"key":"R24-11-20210227","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(06)70729-X","article-title":"Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor in metastatic alveolar soft part sarcoma.","volume":"7","author":"Azizi","year":"2006","journal-title":"Lancet Oncol"},{"key":"R25-11-20210227","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/pbc.21860","article-title":"Bevacizumab treatment in multifocal lymphangioendotheliomatosis with thrombocytopenia.","volume":"52","author":"Kline","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R26-11-20210227","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab.","volume":"29","author":"Choueiri","year":"2011","journal-title":"J Clin Oncol"},{"key":"R27-11-20210227","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R28-11-20210227","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.","volume":"20","author":"Scartozzi","year":"2009","journal-title":"Ann Oncol"},{"key":"R29-11-20210227","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1200\/JCO.2001.19.13.3163","article-title":"Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study.","volume":"19","author":"Mertens","year":"2001","journal-title":"J Clin Oncol"},{"key":"R30-11-20210227","doi-asserted-by":"crossref","first-page":"942090","DOI":"10.4061\/2011\/942090","article-title":"Review of cardiotoxicity in pediatric cancer patients: during and after therapy.","volume":"2011","author":"Fulbright","year":"2011","journal-title":"Cardiol Res Pract"},{"key":"R31-11-20210227","doi-asserted-by":"crossref","first-page":"e560","DOI":"10.1200\/JCO.2011.35.5008","article-title":"Cardiotoxicity in patients treated with bevacizumab is potentially reversible.","volume":"29","author":"Hawkes","year":"2011","journal-title":"J Clin Oncol"},{"key":"R32-11-20210227","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.","volume":"290","author":"Kamba","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0b013e32835b9589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:17:52Z","timestamp":1620947872000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-201302000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32835b9589","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}